Sensorion SA
PAR:ALSEN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sensorion SA
Total Liabilities
Sensorion SA
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sensorion SA
PAR:ALSEN
|
Total Liabilities
€13.4m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
14%
|
|
|
Valneva SE
PAR:VLA
|
Total Liabilities
€292.7m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
8%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Liabilities
€181.6m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
29%
|
|
|
Inventiva SA
PAR:IVA
|
Total Liabilities
€187.9m
|
CAGR 3-Years
39%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Total Liabilities
$64.6m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
12%
|
|
|
Abivax SA
PAR:ABVX
|
Total Liabilities
€164.6m
|
CAGR 3-Years
34%
|
CAGR 5-Years
20%
|
CAGR 10-Years
36%
|
|
Sensorion SA
Glance View
Sensorion SAS is a biopharmaceutical company, which engages in the development of therapies to treat and prevent diseases of the inner ear such as deafness, vertigo and tinnitus. The company is headquartered in Montpellier, Occitanie and currently employs 34 full-time employees. The company went IPO on 2015-04-21. The firm is principally active in the development of targeted therapeutic solutions to treat inner ear diseases. The firm develops also drug treatments, from molecular biology all the way to animal pharmacology, toxicology, and clinical research and therapeutic solutions to treat vestibular deficits. Sensorion SA is a spin-off of the research team Pathophysiology and Therapy of Vestibular Deficits in Montpellier Neuroscience Institute.
See Also
What is Sensorion SA's Total Liabilities?
Total Liabilities
13.4m
EUR
Based on the financial report for Dec 31, 2025, Sensorion SA's Total Liabilities amounts to 13.4m EUR.
What is Sensorion SA's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
14%
Over the last year, the Total Liabilities growth was -22%. The average annual Total Liabilities growth rates for Sensorion SA have been -8% over the past three years , 7% over the past five years , and 14% over the past ten years .
